Spoken Alpha
AbbVie Inc.
AbbVie Inc. develops and markets biopharmaceutical products and medical devices across immunology, neuroscience, oncology, aesthetics, and eye care, selling to physicians, hospitals, pharmacies, and government agencies worldwide.
AbbVie Inc is a Healthcare company operating in Drug Manufacturers - General with a $454.36B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 29, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ABBV.
$ curl https://api.spokenalpha.com/v1/companies/ABBVFAQ
Spoken Alpha indexes ABBV's earnings call transcripts at https://spokenalpha.com/companies/ABBV. Each call links to attributed speakers and parsed analyst Q&A. AbbVie Inc.'s own investor relations page is at https://investors.abbvie.com/.
AbbVie Inc. (ABBV) held its most recent earnings call on 2026-07-31, covering fiscal Q2 2026.
AbbVie Inc. (ABBV) operates in the Healthcare sector (Drug Manufacturers - General industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-29 | — | $3.86 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-30 | $3.65 | $3.64 | +0.3% | $16.99B | — | — | EODHD |
| Q1 FY2026 | 2026-04-28 | $2.65 | $2.67 | -0.8% | $15.00B | — | — | EODHD |
| Q4 FY2025 | 2026-02-03 | $2.71 | $2.65 | +2.3% | $16.62B | — | — | EODHD |
| Q3 FY2025 | 2025-10-30 | $1.86 | $1.78 | +4.5% | $15.78B | — | — | EODHD |
| Q2 FY2025 | 2025-07-30 | $2.97 | $2.91 | +2.1% | $15.42B | — | — | EODHD |
| Q1 FY2025 | 2025-04-24 | $2.46 | $2.40 | +2.5% | $13.34B | — | — | EODHD |
| Q4 FY2024 | 2025-01-30 | $2.16 | $2.12 | +1.9% | $15.10B | — | — | EODHD |
| Q3 FY2024 | 2024-10-29 | $3.00 | $2.92 | +2.7% | $14.46B | — | — | EODHD |
| Q2 FY2024 | 2024-07-24 | $2.65 | $2.66 | -0.4% | $14.46B | — | — | EODHD |
| Q1 FY2024 | 2024-04-25 | $2.31 | $2.23 | +3.6% | $12.31B | — | — | EODHD |
| Q4 FY2023 | 2024-02-01 | $2.79 | $2.77 | +0.7% | $14.30B | — | — | EODHD |
| Q3 FY2023 | 2023-10-26 | $2.95 | $2.87 | +2.8% | $13.93B | — | — | EODHD |
| Q2 FY2023 | 2023-07-26 | $2.91 | $2.81 | +3.6% | $13.87B | — | — | EODHD |
| Q1 FY2023 | 2023-04-26 | $2.46 | $2.49 | -1.2% | $12.22B | — | — | EODHD |
| Q4 FY2022 | 2023-02-08 | $3.60 | $3.58 | +0.6% | $15.12B | — | — | EODHD |
| Q3 FY2022 | 2022-10-27 | $3.66 | $3.57 | +2.5% | $14.81B | — | — | EODHD |
| Q2 FY2022 | 2022-07-28 | $3.37 | $3.31 | +1.8% | $14.58B | — | — | EODHD |
| Q1 FY2022 | 2022-04-28 | $3.16 | $3.14 | +0.6% | $13.54B | — | — | EODHD |
| Q4 FY2021 | 2022-02-01 | $3.31 | $3.28 | +0.9% | $14.89B | — | — | EODHD |
Source: EODHD. ABBV reported actuals as published; sparse fields render as —.